KRAS GENE MUTATION
Clinical trials for KRAS GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS GENE MUTATION trials appear
Sign up with your email to follow new studies for KRAS GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat lung cancer
Disease control OngoingThis phase II trial is testing whether combining the targeted drug trametinib with the chemotherapy docetaxel can shrink tumors in people with advanced KRAS-mutant non-small cell lung cancer. The study enrolls 60 patients whose cancer has worsened after one or two prior treatment…
Matched conditions: KRAS GENE MUTATION
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for tough colorectal cancer: drug combo shows promise
Disease control OngoingThis study tests two drugs, panitumumab and trametinib, in people with stage IV colorectal cancer that no longer responds to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth. About 59 participants will receive either panitumumab alone…
Matched conditions: KRAS GENE MUTATION
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New pill aimed at Hard-to-Treat lung cancer shows early promise
Disease control OngoingThis phase 2 trial is testing an experimental drug called TVB-2640 in 18 people with a specific type of advanced lung cancer that has a KRAS mutation and has not responded to standard treatments. Participants take the drug as a pill once daily for 8 weeks. The study aims to see i…
Matched conditions: KRAS GENE MUTATION
Phase: PHASE2 • Sponsor: David E Gerber • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC